Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups

Yoshiyuki Soeda, Misato Yoshikawa, Osborne F X Almeida, Akio Sumioka, Sumihiro Maeda, Hiroyuki Osada, Yasumitsu Kondoh, Akiko Saito, Tomohiro Miyasaka, Tetsuya Kimura, Masaaki Suzuki, Hiroko Koyama, Yuji Yoshiike, Hachiro Sugimoto, Yasuo Ihara, Akihiko Takashima

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.

Original languageEnglish
Article number10216
JournalNature Communications
Volume6
DOIs
Publication statusPublished - 2015 Dec 16
Externally publishedYes

Fingerprint

Neurofibrillary Tangles
Poisons
cysteine
oligomers
Oligomers
Cysteine
progressions
brain
Brain
adrenergics
Adrenergic Agonists
chemical compounds
Alzheimer Disease
Chemical compounds
detergents
Tauopathies
musculoskeletal system
Isoproterenol
caps
Detergents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. / Soeda, Yoshiyuki; Yoshikawa, Misato; Almeida, Osborne F X; Sumioka, Akio; Maeda, Sumihiro; Osada, Hiroyuki; Kondoh, Yasumitsu; Saito, Akiko; Miyasaka, Tomohiro; Kimura, Tetsuya; Suzuki, Masaaki; Koyama, Hiroko; Yoshiike, Yuji; Sugimoto, Hachiro; Ihara, Yasuo; Takashima, Akihiko.

In: Nature Communications, Vol. 6, 10216, 16.12.2015.

Research output: Contribution to journalArticle

Soeda, Y, Yoshikawa, M, Almeida, OFX, Sumioka, A, Maeda, S, Osada, H, Kondoh, Y, Saito, A, Miyasaka, T, Kimura, T, Suzuki, M, Koyama, H, Yoshiike, Y, Sugimoto, H, Ihara, Y & Takashima, A 2015, 'Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups', Nature Communications, vol. 6, 10216. https://doi.org/10.1038/ncomms10216
Soeda, Yoshiyuki ; Yoshikawa, Misato ; Almeida, Osborne F X ; Sumioka, Akio ; Maeda, Sumihiro ; Osada, Hiroyuki ; Kondoh, Yasumitsu ; Saito, Akiko ; Miyasaka, Tomohiro ; Kimura, Tetsuya ; Suzuki, Masaaki ; Koyama, Hiroko ; Yoshiike, Yuji ; Sugimoto, Hachiro ; Ihara, Yasuo ; Takashima, Akihiko. / Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. In: Nature Communications. 2015 ; Vol. 6.
@article{c5a7135a2c94451f8c81e852efc58e3d,
title = "Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups",
abstract = "Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.",
author = "Yoshiyuki Soeda and Misato Yoshikawa and Almeida, {Osborne F X} and Akio Sumioka and Sumihiro Maeda and Hiroyuki Osada and Yasumitsu Kondoh and Akiko Saito and Tomohiro Miyasaka and Tetsuya Kimura and Masaaki Suzuki and Hiroko Koyama and Yuji Yoshiike and Hachiro Sugimoto and Yasuo Ihara and Akihiko Takashima",
year = "2015",
month = "12",
day = "16",
doi = "10.1038/ncomms10216",
language = "English",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups

AU - Soeda, Yoshiyuki

AU - Yoshikawa, Misato

AU - Almeida, Osborne F X

AU - Sumioka, Akio

AU - Maeda, Sumihiro

AU - Osada, Hiroyuki

AU - Kondoh, Yasumitsu

AU - Saito, Akiko

AU - Miyasaka, Tomohiro

AU - Kimura, Tetsuya

AU - Suzuki, Masaaki

AU - Koyama, Hiroko

AU - Yoshiike, Yuji

AU - Sugimoto, Hachiro

AU - Ihara, Yasuo

AU - Takashima, Akihiko

PY - 2015/12/16

Y1 - 2015/12/16

N2 - Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.

AB - Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils, are a pathological hallmark of Alzheimers disease; the neurofibrillary tangle load correlates strongly with clinical progression of the disease. A growing body of evidence indicates that tau oligomer formation precedes the appearance of neurofibrillary tangles and contributes to neuronal loss. Here we show that tau oligomer formation can be inhibited by compounds whose chemical backbone includes 1,2-dihydroxybenzene. Specifically, we demonstrate that 1,2-dihydroxybenzene-containing compounds bind to and cap cysteine residues of tau and prevent its aggregation by hindering interactions between tau molecules. Further, we show that orally administered DL-isoproterenol, an adrenergic receptor agonist whose skeleton includes 1,2-dihydroxybenzene and which penetrates the brain, reduces the levels of detergent-insoluble tau, neuronal loss and reverses neurofibrillary tangle-associated brain dysfunction. Thus, compounds that target the cysteine residues of tau may prove useful in halting the progression of Alzheimers disease and other tauopathies.

UR - http://www.scopus.com/inward/record.url?scp=84951843847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951843847&partnerID=8YFLogxK

U2 - 10.1038/ncomms10216

DO - 10.1038/ncomms10216

M3 - Article

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10216

ER -